Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
In hepatocellular carcinoma (HCC), the clinical significance of soluble immune checkpoint protein levels as predictors of patient outcomes or therapeutic responses has yet to be defined. This study profiled the baseline levels of sixteen soluble checkpoint proteins and their changes following sorafenib treatment for HCC. Plasma samples were obtained from 53 patients with advanced HCC at baseline, week 1, 2 and 4 of sorafenib treatment and tested the concentrations of 16 soluble checkpoint proteins using multiplexed fluorescent bead-based immunoassays. Multivariate analysis showed high sBTLA levels at baseline were an independent predictor of poor overall survival (p = 0.038). BTLA was highly expressed in T cells and macrophages in peritumoral areas. At week 2, sCD27 levels were decreased compared to baseline. By contrast, the concentrations of most inhibitory proteins, including sBTLA, sLAG-3, sCTLA-4, sPD-1, sCD80, sCD86 and sPD-L1, had significantly increased. The fold-changes of soluble checkpoint receptors and their ligands, including sCTLA-4 with sCD80/sCD86, sPD-1 with sPD-L1; and the fold-changes of sCTLA-4 with sBTLA or sPD-1 were positively correlated. sBTLA may be a good biomarker for predicting overall survival in HCC patients. Sorafenib treatment in patients with advanced HCC revealed dynamic changes of soluble checkpoint protein levels.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7042216 | PMC |
| http://dx.doi.org/10.1038/s41598-020-60440-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
ENPP1 inhibitor with ultralong drug-target residence time as an innate immune checkpoint blockade cancer therapy.
Cell Rep Med
August 2025
Department of Biochemistry, Stanford University, Stanford, CA 94305, USA; ChEM-H Institute, Stanford University, Stanford, CA 94305, USA; Arc Institute, Palo Alto, CA 94304, USA. Electronic address:
Only one in five patients respond to immune checkpoint inhibitors, which primarily target adaptive immunity. Ectonucleotide pyrophosphatase/phophodiesterase 1 (ENPP1), the dominant hydrolase of 2'3'-cyclic-GMP-AMP (cGAMP) that suppresses downstream stimulator of interferon genes (STING) signaling, has emerged as a promising innate immunotherapy target. However, existing ENPP1 inhibitors have been optimized for prolonged systemic residence time rather than effective target inhibition within tumors.
View Article and Find Full Text PDFElevated FDG uptake in non-tumorous lung regions does not predict immune checkpoint inhibitor-related pneumonitis in lung cancer patients.
Front Oncol
August 2025
German Center for Lung Research (Deutsches Zentrum für Lungenforschung (DZL)) (Comprehensive Pneumology Center - Munich (CPC-M)), Munich, Germany.
Background: Predictors for checkpoint inhibitor-related pneumonitis (cinrPneumonitis) are desperately needed. This study aimed to investigate the pretreatment standardized uptake value (SUV) on [F]FDG-PET/CT of non-tumorous lung tissue as a predictive imaging marker for the development of cinrPneumonitis in 239 patients with lung cancer.
Methods: All patients with lung cancer receiving [F]Fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) prior to immune checkpoint inhibitor (ICI) therapy were included and retrospectively analyzed.
Immune checkpoints in immune response to glioma: two sides of the same coin.
Front Immunol
September 2025
Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Science, Moscow, Russia.
Gliomas are aggressive brain tumors of glial origin accounting for about 80% of the central nervous system (CNS) malignancies. Glioma cells are known to form a highly immunosuppressive tumor microenvironment (TME) capable of inhibiting T cell activation and protecting tumors from elimination by the immune system. One of the predominant immune inhibitory mechanisms in the TME are immune checkpoints: a complex system of membrane-bound ligands on tumor and immune cells that interact with surface receptors on T lymphocytes and affect their activation and cytotoxicity.
View Article and Find Full Text PDFSoluble IL-2 receptor levels support diagnosis of sarcoidosis-like reaction in melanoma patients on immunotherapy - a diagnostic algorithm based on a single center retrospective study.
J Dtsch Dermatol Ges
August 2025
Department of Dermatology, Venereology and Allergology, University Medical Center Leipzig, Leipzig, Germany.
Background And Objectives: Drug-induced sarcoidosis-like reaction (DISR) is an adverse event with emerging importance during immune checkpoint inhibitor (ICI) treatment in melanoma patients. Its reported frequency varies widely, making accurate diagnosis crucial. Distinguishing DISR from tumor progression is challenging, and misdiagnosis may lead to detrimental treatment changes.
View Article and Find Full Text PDFAssociation of Soluble Immune Checkpoint Molecules PD1 and 4-1BB With CTLA-4Ig Treatment Response in Early Rheumatoid Arthritis.
ACR Open Rheumatol
July 2025
Department of Rheumatology and Inflammation Research, Sahlgrenska Academy at University of Gothenburg and Department of Rheumatology, Sahlgrenska University Hospital, Gothenburg, Sweden.
Objective: To investigate whether soluble immune checkpoint molecules in blood are associated with the treatment response to disease-modifying antirheumatic drugs in early rheumatoid arthritis (eRA).
Methods: This study included 328 Swedish treatment-naïve patients with eRA from the Nordic Rheumatic Diseases Strategy Trials and Registries (NORD-STAR) study. Patients were randomized into four treatment groups: methotrexate (MTX) combined with CTLA-4Ig (n = 90), anti-tumor necrosis factor (n = 83), anti-interleukin-6 receptor (n = 76), or prednisolone (n = 79).